New Crestor® Death Reported

Return to Crestor® homepage on SSEM.COM

AstraZeneca's cholesterol-lowering drug Crestor® has been linked to the death of a patient, the drugmaker said on January 10.

The death, possibly due to the severe muscle-wasting condition rhabdomyolysis, has been reported to regulators worldwide, company spokesman Steve Brown said.

Brown said the circumstances surrounding the death, which occurred in December of 2004, were complicated and the company still believed Crestor's® safety profile was similar to that of other statin drugs.

"AstraZeneca confirms that a death, possibly attributed to rhabdomyolysis, associated with Crestor® has been reported. The case details are complex with clinical features more consistent with neuroleptic malignant syndrome, a condition seen with antipsychotic agents," Brown said in response to inquires.

AstraZeneca noted that more than 14 million prescriptions for over 4 million patients had been written for Crestor® worldwide.

If you believe that you or a relative were injured by taking Crestor® please use the form below to contact our law firm.

Have you suffered kidney damage or symptoms of Rhabdomyolysis? (Select Yes or No)
YES
NO

Your Name:

Your E-Mail:

Your Daytime Phone Number:

Your Evening Phone Number:

Please fill in your question or comments:

References

Copyright © 1999-2008 Specter Specter Evans & Manogue, P.C.
Terms of Use | Privacy Policy